James C. Yao, MD

Peer-Reviewed Articles

1. Chamseddine, SM, Yavuz, BG, Mohamed, Y, Lee, SS, Yao, JC, Hu, Z, Lapelusa, M, Xiao, L, Sun, R, Morris, JS, Hatia, RI, Hassan, MM, Duda, DG, Diab, M, Mohamed, A, Nassar, A, Amin, H, Kaseb, A. Circulating Galectin-3. Journal of Immunotherapy and Precision Oncology 7(4):255-262, 2024. e-Pub 2024.
2. Mohamed, YI, Lee, SS, Demir, T, Chamseddine, SM, Hu, ZI, Xiao, L, Elsayes, KM, Morris, JS, Wolff, RA, Hiatia, R, Qayyum, A, Rashid, A, Duda, DG, Yao, JC, Lapelusa, M, Koay, EJ, Mahvash, A, Al Azzam, A, Ileana Dumbrava, EE, Hassan, MM, Amin, HM, Kaseb, A. Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab. Cancer Biomarkers 41(1):83-91, 2024. e-Pub 2024. PMID: 39269823.
3. Tran Cao HS, Witt RG, Elsayes KM, Baiomy AA, Xiao L, Palmquist S, Lee SS, Mohamed YI, Mahvash A, Tzeng CD, Chun YS, Koay EJ, Rashid A, Hassan MM, Yao JC, Vauthey JN, Kaseb AO. Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features. Oncologist 29(6):e803-e810, 2024. e-Pub 2023. PMID: 38159256.
4. Lv JL, Tan YJ, Ren YS, Ma R, Wang X, Wang SY, Liu WQ, Zheng QS, Yao JC, Tian J, Li J. Procyanidin C1 inhibits tumor growth and metastasis in colon cancer via modulating miR-501-3p/HIGD1A axis. J Adv Res 60:215-231, 2024. e-Pub 2024. PMID: 37479180.
5. Sewastjanow-Silva M, Xiao L, Gonzalez GN, Wang X, Hofstetter W, Swisher S, Mehran R, Sepesi B, Bhutani MS, Weston B, Coronel E, Waters RE, Rogers JE, Smith J, Lyons L, Reilly N, Yao JC, Ajani JA, Murphy MB. Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study. Cancers (Basel) 16(7), 2024. e-Pub 2024. PMID: 38611056.
6. Cordero-Hernandez, IS, Ross, AC, Dasari, NV, Halperin, DM, Chasen, B, Yao, JC. Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy. Endocrine-related cancer 31(4), 2024. e-Pub 2024. PMID: 38329269.
7. Chamseddine S, LaPelusa M, Xiao L, Mohamed YI, Lee SS, Hu ZI, Hatia RI, Hassan M, Yao JC, Duda DG, Datar S, Amin HM, Kaseb AO. Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma. J Hepatocell Carcinoma 11:455-461, 2024. e-Pub 2024. PMID: 38463542.
8. Liu Y, Wei D, Deguchi Y, Xu W, Tian R, Liu F, Xu M, Mao F, Li D, Chen W, Valentin LA, Deguchi E, Yao JC, Shureiqi I, Zuo X. PPARδ dysregulation of CCL20/CCR6 axis promotes gastric adenocarcinoma carcinogenesis by remodeling gastric tumor microenvironment. Gastric Cancer 26(6):904-917, 2023. e-Pub 2023. PMID: 37572185.
9. Chamseddine S, Mohamed YI, Lee SS, Yao JC, Hu ZI, Tran Cao HS, Xiao L, Sun R, Morris JS, Hatia RI, Hassan M, Duda DG, Diab M, Mohamed A, Nassar A, Datar S, Amin HM, Kaseb AO. Clinical and Prognostic Biomarker Value of Blood Circulating Inflammatory Cytokines in Hepatocellular Carcinoma. Oncology 101(11):730-737, 2023. e-Pub 2023. PMID: 37467732.
10. Singh S, Hope TA, Bergsland EB, Bodei L, Bushnell DL, Chan JA, Chasen BR, Chauhan A, Das S, Dasari A, Del Rivero J, El-Haddad G, Goodman KA, Halperin DM, Lewis MA, Lindwasser OW, Myrehaug S, Raj NP, Reidy-Lagunes DL, Soares HP, Strosberg JR, Kohn EC, Kunz PL, participants NET. Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting. J Natl Cancer Inst 115(9):1001-1010, 2023. e-Pub 2023. PMID: 37255328.
11. Shih YT, Xu Y, Yao JC. Financial Outcomes of "Bagging" Oncology Drugs Among Privately Insured Patients With Cancer. JAMA Netw Open 6(9):e2332643, 2023. e-Pub 2023. PMID: 37676663.
12. Noh S, Bertini C, Mira-Avendano I, Kaous M, Patel B, Faiz SA, Shannon VR, Balachandran DD, Bashoura L, Adachi R, Evans SE, Dickey B, Wu C, Shroff GS, Manzano JG, Granwehr B, Holloway S, Dickson K, Mohammed A, Muthu M, Song H, Team D, Chung C, Wu J, Lee L, Jiang Y, Khawaja F, Sheshadri A. Interstitial lung abnormalities after hospitalization for COVID-19 in patients with cancer: A prospective cohort study. Cancer Med. e-Pub 2023. PMID: 37592894.
13. Liu CZ, Liu XB, Sun J, Yu CQ, Yao JC, Liu Z, Hao JC. IL-8-induced CXCR2 down-regulation in circulating monocytes in hepatocellular carcinoma is partially dependent on MAGL. BMC Cancer 23(1):626, 2023. e-Pub 2023. PMID: 37403022.
14. Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, García-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csoszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C, Investigators FS. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet 402(10395):41-53, 2023. e-Pub 2023. PMID: 37331369.
15. Osterman TJ, Yao JC, Krzyzanowska MK. Implementing Innovation: Informatics-Based Technologies to Improve Care Delivery and Clinical Research. Am Soc Clin Oncol Educ Book 43:e389880, 2023. e-Pub 2023. PMID: 37216629.
16. Reddy DR, Cuenca JA, Botdorf J, Muthu M, Hanmandlu A, Wegner R, Crommett J, Gutierrez C, Rathi N, Sajith B, Knafl M, Abbas HA, Woodman SE, Nates JL, Collaborators DT. Clinical Characteristics and Cause of Death Among Hospitalized Decedents With Cancer and COVID-19. Mayo Clin Proc 98(3):451-457, 2023. e-Pub 2023. PMID: 36868753.
17. Kunz PL, Graham NT, Catalano PJ, Nimeiri HS, Fisher GA, Longacre TA, Suarez CJ, Martin BA, Yao JC, Kulke MH, Hendifar AE, Shanks JC, Shah MH, Zalupski MM, Schmulbach EL, Reidy-Lagunes DL, Strosberg JR, O'Dwyer PJ, Benson AB. A Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). J Clin Oncol 41(7):101200JCO2201013, 2023. e-Pub 2023. PMID: 36260828.
18. Sobrero, A, Dasari, NV, Lonardi, S, Garcia-Carbonero, R, Elez, E, Yoshino, T, Yao, JC, Garcia-Alfonso, P, Kocsis, J, Cubillo, A, Sartore-Bianchi, A, Satoh, T, Randrian, V, Tomasek, J, Chong, G, Yang, Z, Schelman, WR, Kania, M, Tabernero, J, Eng, C. Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study. Journal of Clinical Oncology 41(4):67, 2023. e-Pub 2023.
19. Honan, KA, Hassan, SA, Deswal, A, Herrmann, J, Song, J, Monlezun, DJ, Halperin, DM, Mahvash, A, Dasari, NV, Koutroumpakis, E, Akay, MH, Balanescu, DV, de Armas, IS, Patel, MK, Nathan, S, Kar, B, Marmagkiolis, K, Lopez-Mattei, J, Patel, J, Gregoric, ID, Yao, JC, Iliescu, C. Bioprosthetic valve monitoring in patients with carcinoid heart disease. Frontiers in Cardiovascular Medicine 9, 2023. e-Pub 2023. PMID: 36712267.
20. Yao JC, Yao GJ, Wang ZH, Yan XJ, Lu QQ, Li W, Liu YD. Bioaugmentation of intertidal sludge enhancing the development of salt-tolerant aerobic granular sludge. J Environ Manage 325(Pt B):116394, 2023. e-Pub 2023. PMID: 36323127.
21. Mohamed YI, Duda DG, Awiwi MO, Lee SS, Altameemi L, Xiao L, Morris JS, Wolff RA, Elsayes KM, Hatia RI, Qayyum A, Chamseddine SM, Rashid A, Yao JC, Mahvash A, Hassan MM, Amin HM, Kaseb AO. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients. Oncotarget 13(1):1314-1321, 2022. e-Pub 2022. PMID: 36473155.
22. Shih YT, Xu Y, Bradley C, Giordano SH, Yao J, Yabroff KR. Costs Around the First Year of Diagnosis for 4 Common Cancers Among the Privately Insured. J Natl Cancer Inst 114(10):1392-1399, 2022. e-Pub 2022. PMID: 36099068.
23. Halperin DM, Liu S, Dasari A, Fogelman D, Bhosale P, Mahvash A, Estrella JS, Rubin L, Morani AC, Knafl M, Overeem TA, Fu SC, Solis LM, Parra Cuentas E, Verma A, Chen HL, Gite S, Subashchandrabose P, Dervin S, Schulze K, Darbonne WC, Yun C, Wistuba II, Futreal PA, Woodman SE, Yao JC. Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial. JAMA Oncol 8(6):904-909, 2022. e-Pub 2022. PMID: 35389428.
24. Liu Y, Deguchi Y, Wei D, Liu F, Moussalli MJ, Deguchi E, Li D, Wang H, Valentin LA, Colby JK, Wang J, Zheng X, Ying H, Gagea M, Ji B, Shi J, Yao JC, Zuo X, Shureiqi I. Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ. Nat Commun 13(1):2665, 2022. e-Pub 2022. PMID: 35562376.
25. Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey JN, Lee SS, Yavuz BG, Mohamed YI, Qayyum A, Jindal S, Duan F, Basu S, Yadav SS, Nicholas C, Sun JJ, Singh Raghav KP, Rashid A, Carter K, Chun YS, Tzeng CD, Sakamuri D, Xu L, Sun R, Cristini V, Beretta L, Yao JC, Wolff RA, Allison JP, Sharma P. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 7(3):208-218, 2022. e-Pub 2022. PMID: 35065057.
26. Pudakalakatti S, Titus M, Enriquez JS, Ramachandran S, Zacharias NM, Shureiqi I, Liu Y, Yao JC, Zuo X, Bhattacharya PK. Identifying the Metabolic Signatures of PPARD-Overexpressing Gastric Tumors. Int J Mol Sci 23(3):1645, 2022. e-Pub 2022. PMID: 35163565.
27. Rogers JE, Lam M, Halperin DM, Dagohoy CG, Yao JC, Dasari A. Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. Neuroendocrinology 112(1):34-42, 2022. e-Pub 2022. PMID: 33434908.
28. Kaseb AO, Haque A, Vishwamitra D, Hassan MM, Xiao L, George B, Sahu V, Mohamed YI, Carmagnani Pestana R, Lombardo JL, Avritscher R, Yao JC, Wolff RA, Rashid A, Morris JS, Amin HM. Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma. Front Oncol 12:986305, 2022. e-Pub 2022. PMID: 36276070.
29. Monlezun DJ, Badalamenti A, Javaid A, Marmagkiolis K, Honan K, Kim JW, Patel R, Akhanti B, Halperin D, Dasari A, Koutroumpakis E, Kim P, Lopez-Mattei J, Yusuf SW, Cilingiroglu M, Mamas MA, Gregoric I, Yao J, Hassan S, Iliescu C. Artificial intelligence-augmented analysis of contemporary procedural, mortality, and cost trends in carcinoid heart disease in a large national cohort with a focus on the "forgotten pulmonic valve". Front Cardiovasc Med 9:1071138, 2022. e-Pub 2022. PMID: 36843627.
30. Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP, investigators N. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 22(12):1752-1763, 2021. e-Pub 2021. PMID: 34793718.
31. Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov 11(11):2738-2747, 2021. e-Pub 2021. PMID: 34261675.
32. Shih, YT, Xu, Y, Zhao, H, Schrag, D, Yao, JC. Financial Burden of Discarded Weight-based Antineoplastic Drugs to Payers and Patients in the Private Insurance Market. JNCI Cancer Spectrum 5(4), 2021. e-Pub 2021. PMID: 34350376.
33. Dasari, NV, Sobrero, A, Yao, JC, Yoshino, T, Schelman, WR, Yang, Z, Chien, C, Kania, M, Tabernero, J, Eng, C. FRESCO-2. Future Oncology 17(24):3151-3162, 2021. e-Pub 2021. PMID: 33993740.
34. Fazio N, Carnaghi C, Buzzoni R, Valle JW, Herbst F, Ridolfi A, Strosberg J, Kulke MH, Pavel ME, Yao JC. Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials. Cancer 127(15):2674-2682, 2021. e-Pub 2021. PMID: 33857327.
35. Morris JS, Hassan MM, Zohner YE, Wang Z, Xiao L, Rashid A, Haque A, Abdel-Wahab R, Mohamed YI, Ballard KL, Wolff RA, George B, Li L, Allen G, Weylandt M, Li D, Wang W, Raghav K, Yao J, Amin HM, Kaseb AO. HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk. Hepatology 73(6):2278-2292, 2021. e-Pub 2021. PMID: 32931023.
36. Mohamed, Y, Lee, SS, Xiao, L, Hassan, MM, Qayyum, A, Hiatia, R, Pestana, RC, Haque, MA, George, B, Rashid, A, Duda, DG, Elghazaly, HA, Wolff, RA, Morris, J, Yao, JC, Amin, H, Kaseb, A. Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncotarget 12(8):756-766, 2021. e-Pub 2021. PMID: 33889299.
37. Chan H, Zhang L, Choti MA, Kulke M, Yao JC, Nakakura EK, Bloomston M, Benson AB, Shah MH, Strosberg JR, Bergsland EK, Van Loon K. Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database. Pancreas 50(4):506-512, 2021. e-Pub 2021. PMID: 33939661.
38. Yao JC, Strosberg J, Fazio N, Pavel ME, Bergsland E, Ruszniewski P, Halperin DM, Li D, Tafuto S, Raj N, Campana D, Hijioka S, Raderer M, Guimbaud R, Gajate P, Pusceddu S, Reising A, Degtyarev E, Shilkrut M, Eddy S, Singh S. Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms. Endocr Relat Cancer 28(3):161-172, 2021. e-Pub 2021. PMID: 33480358.
39. Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, Kulke MH, Pavel M, Singh S. Markers of Systemic Inflammation in Neuroendocrine Tumors: A Pooled Analysis of the RADIANT-3 and RADIANT-4 Studies. Pancreas 50(2):130-137, 2021. e-Pub 2021. PMID: 33560090.
40. Shaunfield S, Webster KA, Kaiser K, Greene GJ, Yount SE, Lacson L, Benson AB, Halperin DM, Yao JC, Singh S, Feuilly M, Marteau F, Cella D. Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index (FACT-CSI). Neuroendocrinology 111(9):850-862, 2021. e-Pub 2021. PMID: 32911478.
41. Kaseb AO, Kappadath SC, Lee SS, Raghav KP, Mohamed YI, Xiao L, Morris JS, Ohaji C, Avritscher R, Odisio BC, Kuban J, Abdelsalam ME, Chasen B, Elsayes KM, Elbanan M, Wolff RA, Yao JC, Mahvash A. A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. J Hepatocell Carcinoma 8:1129-1145, 2021. e-Pub 2021. PMID: 34527608.
42. Abdel-Wahab R, Hassan MM, George B, Carmagnani Pestana R, Xiao L, Lacin S, Yalcin S, Shalaby AS, Al-Shamsi HO, Raghav K, Wolff RA, Yao JC, Girard L, Haque A, Duda DG, Dima S, Popescu I, Elghazaly HA, Vauthey JN, Aloia TA, Tzeng CW, Chun YS, Rashid A, Morris JS, Amin HM, Kaseb AO. Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients. Oncology 98(12):836-846, 2020. e-Pub 2020. PMID: 33027788.
43. Wang Y, Janku F, Piha-Paul S, Hess K, Broaddus R, Liu L, Shi N, Overman M, Kopetz S, Subbiah V, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Fu S. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Sci Rep 10(1):3080, 2020. e-Pub 2020. PMID: 32080210.
44. Shen C, Gu D, Zhou S, Xu Y, Sarshekeh AM, Halperin D, Shih YT, Yao JC, Dasari A. Racial Differences in the Incidence and Survival of Patients With Neuroendocrine Tumors. Pancreas 48(10):1373-1379, 2019. e-Pub 2019. PMID: 31688604.
45. Kaseb AO, Sánchez NS, Sen S, Kelley RK, Tan B, Bocobo AG, Lim KH, Abdel-Wahab R, Uemura M, Pestana RC, Qiao W, Xiao L, Morris J, Amin HM, Hassan MM, Rashid A, Banks KC, Lanman RB, Talasaz A, Mills-Shaw KR, George B, Haque A, Raghav KPS, Wolff RA, Yao JC, Meric-Bernstam F, Ikeda S, Kurzrock R. Molecular profiling of hepatocellular carcinoma using circulating cell-free DNA. Clin Cancer Res 25(20):6107-6118, 2019. e-Pub 2019. PMID: 31363003.
46. Romero Arenas MA, Olsen C, Yao JC. Recurrence of Metastatic Pro-insulinoma Nearly 50 Years After Subtotal Pancreatectomy. J Gastrointest Cancer 50(2):345-348, 2019. e-Pub 2019. PMID: 29110229.
47. Yao JC, Garg A, Chen D, Capdevila J, Engstrom P, Pommier R, Van Cutsem E, Singh S, Fazio N, He W, Riester M, Patel P, Voi M, Morrissey M, Pavel ME, Kulke MH. Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials. Endocr Relat Cancer 26(4):391-403, 2019. e-Pub 2019. PMID: 30667365.
48. Samdani RT, Wasylishen AR, Halperin DM, Dasari A, Yao JC, Rashid A, Estrella JS. Loss of Menin Expression by Immunohistochemistry in Pancreatic Neuroendocrine Tumors: Comparison Between Primary and Metastatic Tumors. Pancreas 48(4):510-513, 2019. e-Pub 2019. PMID: 30946241.
49. Halperin DM, Lee JJ, Ng CS, Strosberg JR, Estrella JS, Dagohoy CG, Dasari A, Yao JC. A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors. Pancreas 48(3):381-386, 2019. e-Pub 2019. PMID: 30768575.
50. Yao JC, Oh DY, Qian J, Park YS, Herbst F, Ridolfi A, Izquierdo M, Ito T, Jia L, Komoto I, Sriuranpong V, Shimada Y. Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study. Onco Targets Ther 12:1717-1728, 2019. e-Pub 2019. PMID: 30881026.
51. Shen C, Dasari A, Xu Y, Zhou S, Gu D, Chu Y, Halperin DM, Shih YT, Yao JC. Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study. Sci Rep 8(1):16863, 2018. e-Pub 2018. PMID: 30442902.
52. Shen C, Dasari A, Gu D, Chu Y, Zhou S, Xu Y, Halperin D, Fu S, Yao JC, Shih YT. Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors. Pharmacoeconomics 36(8):1005-1013, 2018. e-Pub 2018. PMID: 29682693.
53. Ng CS, Wei W, Duran C, Ghosh P, Anderson EF, Chandler AG, Yao JC. CT perfusion in normal liver and liver metastases from neuroendocrine tumors treated with targeted antivascular agents. Abdom Radiol (NY) 43(7):1661-1669, 2018. e-Pub 2018. PMID: 29075824.
54. Salazar R, Garcia-Carbonero R, Libutti SK, Hendifar AE, Custodio A, Guimbaud R, Lombard-Bohas C, Ricci S, Klümpen HJ, Capdevila J, Reed N, Walenkamp A, Grande E, Safina S, Meyer T, Kong O, Salomon H, Tavorath R, Yao JC. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors. Oncologist 23(7):766-e90, 2018. e-Pub 2018. PMID: 29242283.
55. Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. J Natl Compr Canc Netw 16(6):693-702, 2018. e-Pub 2018. PMID: 29891520.
56. Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer 124(4):807-815, 2018. e-Pub 2018. PMID: 29211313.
57. Fazio N, Buzzoni R, Delle Fave G, Tesselaar ME, Wolin E, Van Cutsem E, Tomassetti P, Strosberg J, Voi M, Bubuteishvili-Pacaud L, Ridolfi A, Herbst F, Tomasek J, Singh S, Pavel M, Kulke MH, Valle JW, Yao JC. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Sci 109(1):174-181, 2018. e-Pub 2018. PMID: 29055056.
58. Singh S, Carnaghi C, Buzzoni R, Pommier RF, Raderer M, Tomasek J, Lahner H, Valle JW, Voi M, Bubuteishvili-Pacaud L, Lincy J, Wolin E, Okita N, Libutti SK, Oh DY, Kulke M, Strosberg J, Yao JC, Pavel ME, Fazio N, Tumors RAD, Study Group FT. Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary. Neuroendocrinology 106(3):211-220, 2018. e-Pub 2018. PMID: 28554173.
59. Voong KR, Rashid A, Crane CH, Minsky BD, Krishnan S, Yao JC, Wolff RA, Skibber JM, Feig BW, Chang GJ, Das P. Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal. Am J Clin Oncol 40(6):555-560, 2017. e-Pub 2017. PMID: 26237193.
60. Sarshekeh AM, Advani S, Halperin DM, Conrad C, Shen C, Yao JC, Dasari A. Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis. Oncotarget 8(59):99541-99551, 2017. e-Pub 2017. PMID: 29245922.
61. Buzzoni R, Carnaghi C, Strosberg J, Fazio N, Singh S, Herbst F, Ridolfi A, Pavel ME, Wolin EM, Valle JW, Oh DY, Yao JC, Pommier R. Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. Onco Targets Ther 10:5013-5030, 2017. e-Pub 2017.
62. Pavel ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, Degtyarev E, Neary MP, Carnaghi C, Tomasek J, Wolin E, Raderer M, Lahner H, Valle JW, Pommier R, Van Cutsem E, Tesselaar MET, Fave GD, Buzzoni R, Hunger M, Eriksson J, Cella D, Ricci JF, Fazio N, Kulke MH, Yao JC. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18(10):1411-1422, 2017. e-Pub 2017. PMID: 28838862.
63. Pavel ME, Chen D, He W, Cushman S, Voi M, de Vries EGE, Baudin E, Yao JC. Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors. Pancreas 46(6):751-757, 2017. e-Pub 2017. PMID: 28609362.
64. Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O'Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas 46(6):707-714, 2017. e-Pub 2017. PMID: 28609356.
65. Pavel ME, Baudin E, Öberg KE, Hainsworth JD, Voi M, Rouyrre N, Peeters M, Gross DJ, Yao JC. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. Ann Oncol 28(7):1569-1575, 2017. e-Pub 2017. PMID: 28444114.
66. Shen C, Dasari A, Chu Y, Halperin DM, Zhou S, Xu Y, Shih YT, Yao JC. Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors. Ann Oncol 28(7):1582-1589, 2017. e-Pub 2017. PMID: 28444105.
67. Kulke MH, Ruszniewski P, Van Cutsem E, Lombard-Bohas C, Valle JW, De Herder WW, Pavel M, Degtyarev E, Brase JC, Bubuteishvili-Pacaud L, Voi M, Salazar R, Borbath I, Fazio N, Smith D, Capdevila J, Riechelmann RP, Yao JC. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Ann Oncol 28(6):1309-1315, 2017. e-Pub 2017. PMID: 28327907.
68. Shen C, Chu Y, Halperin DM, Dasari A, Zhou S, Xu Y, Yao JC, Shih YT. Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. Oncologist 22(12). e-Pub 2017. PMID: 28642335.
69. Yao JC, Guthrie KA, Moran C, Strosberg JR, Kulke MH, Chan JA, LoConte N, McWilliams RR, Wolin EM, Mattar B, McDonough S, Chen H, Blanke CD, Hochster HS. Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35(15):JCO2016704072. e-Pub 2017. PMID: 28384065.
70. Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, Shih YT, Yao JC. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol 18(4):525-534, 2017. e-Pub 2017. PMID: 28238592.
71. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 3(10). e-Pub 2017. PMID: 28448665.
72. Tang C, Sherman SI, Price M, Weng J, Davis SE, Hong DS, Yao JC, Buzdar A, Wilding G, Lee JJ. Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement. Clin Cancer Res 23(6):1414-1421, 2017. e-Pub 2017. PMID: 28275168.
73. Qiu W, Christakis I, Stewart AA, Vodopivec DM, Silva-Figueroa A, Chen H, Woodard TL, Halperin DM, Lee JE, Yao JC, Perrier ND. Is estrogen exposure a protective factor for pancreatic neuroendocrine tumours in female patients with multiple endocrine neoplasia syndrome type 1?. Clin Endocrinol (Oxf) 86(6). e-Pub 2017. PMID: 28273369.
74. Roland CL, Starker LF, Kang Y, Chatterjee D, Estrella J, Rashid A, Katz MH, Aloia TA, Lee JE, Dasari A, Yao JC, Fleming JB. Loss of DPC4/SMAD4 expression in primary gastrointestinal neuroendocrine tumors is associated with cancer-related death after resection. Surgery 161(3):753-759, 2017. e-Pub 2017. PMID: 27816207.
75. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao JC, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E, Investigators NT. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 376(2):125-135, 2017. e-Pub 2017. PMID: 28076709.
76. Al-Shamsi HO, Abdel-Wahab R, Hassan MM, Shalaby AS, Dahbour I, Lacin S, Mahvash A, Odisio BC, Murthy R, Avritscher R, Abdelsalam ME, Rashid A, Vauthey JN, Aloia TA, Conrad C, Chun YS, Krishnan S, Das P, Koay EJ, Amin HM, Yao JC, Kaseb AO. Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States. Oncology 93(4):233-242, 2017. e-Pub 2017. PMID: 28683459.
77. Yao JC, Chan JA, Mita AC, Kundu MG, Hermosillo Reséndiz K, Hu K, Ravichandran S, Strosberg JR, Wolin EM. Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors. Onco Targets Ther 10:3177-3186, 2017. e-Pub 2017. PMID: 28721067.
78. Halperin DM, Yao JC, Dasari A. What's in a Name? Steady Progress in Staging Pancreatic Neuroendocrine Tumors. J Clin Oncol:JCO2016707364. e-Pub 2016. PMID: 27893328.
79. Pavel ME, Becerra C, Grosch K, Cheung W, Hasskarl J, Yao JC. Effect of everolimus on the pharmacokinetics of octreotide long-acting repeatable in patients with advanced neuroendocrine tumors: An analysis of the randomized phase III RADIANT-2 trial. Clin Pharmacol Ther. e-Pub 2016. PMID: 28032910.
80. Yao JC, Pavel M, Lombard-Bohas C, Van Cutsem E, Voi M, Brandt U, He W, Chen D, Capdevila J, de Vries EG, Tomassetti P, Hobday T, Pommier R, Öberg K. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. J Clin Oncol. e-Pub 2016. PMID: 27621394.
81. Halperin DM, Dasari A, Yao JC. Future Directions in the Biology of Neuroendocrine Tumors. Pancreas 45(6):783-5, 2016. e-Pub 2016. PMID: 27295529.
82. Qiu W, Christakis I, Silva A, Bassett RL, Cao L, Meng QH, Gardner Grubbs E, Zhao H, Yao JC, Lee JE, Perrier ND. Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients. Clin Endocrinol (Oxf). e-Pub 2016. PMID: 27256431.
83. Shen C, Xu Y, Dasari A, Shih YC, Yao JC. Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors. Oncologist 21(3):308-13, 2016. e-Pub 2016. PMID: 26911407.
84. Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Delle Fave G, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME, Tumours RAD, Study Group FT. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387(10022):968-77, 2016. e-Pub 2016. PMID: 26703889.
85. Halperin DM, Dasari A, Yao JC. [(177)Lu-DOTA(0),Tyr(3)]-octreotate in the treatment of midgut neuroendocrine tumors. Future Oncol 12(3):313-21, 2016. e-Pub 2016. PMID: 26759064.
86. Mahvash A, Murthy R, Odisio BC, Raghav KP, Girard L, Cheung S, Nguyen V, Ensor J, Gadani S, Elsayes KM, Abdel-Wahab R, Hassan M, Shalaby AS, Yao JC, Wallace MJ, Kaseb AO. Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatocell Carcinoma 3:1-7, 2016. e-Pub 2016. PMID: 27574586.
87. Kaseb AO, Morris JS, Iwasaki M, Al-Shamsi HO, Raghav KP, Girard L, Cheung S, Nguyen V, Elsayes KM, Xiao L, Abdel-Wahab R, Shalaby AS, Hassan M, Hassabo HM, Wolff RA, Yao JC. Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. Onco Targets Ther 9:773-80, 2016. e-Pub 2016. PMID: 26929648.
88. Strosberg JR, Yao JC, Bajetta E, Aout M, Bakker B, Hainsworth JD, Ruszniewski PB, Van Cutsem E, Öberg K, Pavel ME. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis. Endocr Relat Cancer 22(6):933-40, 2015. e-Pub 2015. PMID: 26373569.
89. Conte B, George B, Overman M, Estrella J, Jiang ZQ, Mehrvarz Sarshekeh A, Ferrarotto R, Hoff PM, Rashid A, Yao JC, Kopetz S, Dasari A. High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. Clin Colorectal Cancer. e-Pub 2015. PMID: 26810202.
90. Raghav KP, Mahajan S, Yao JC, Hobbs BP, Berry DA, Pentz RD, Tam A, Hong WK, Ellis LM, Abbruzzese J, Overman MJ. From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology. J Clin Oncol 33(31):3583-90, 2015. e-Pub 2015. PMID: 26304898.
91. Halperin DM, Lee JJ, Dagohoy CG, Yao JC. Rational Clinical Experiment: Assessing Prior Probability and Its Impact on the Success of Phase II Clinical Trials. J Clin Oncol 33(26):2914-9, 2015. e-Pub 2015. PMID: 26261263.
92. Shen C, Shih YT, Xu Y, Yao JC. Octreotide LAR among elderly patients with neuroendocrine tumors: A Survival analysis of SEER-Medicare data. Cancer Epidemiol Biomarkers Prev. e-Pub 2015. PMID: 26315553.
93. Phan AT, Halperin DM, Chan JA, Fogelman DR, Hess KR, Malinowski P, Regan E, Ng CS, Yao JC, Kulke MH. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol 16(6):695-703, 2015. e-Pub 2015. PMID: 25956795.
94. Ng CS, Hobbs BP, Wei W, Anderson EF, Herron DH, Yao JC, Chandler AG. Effect on Perfusion Values of Sampling Interval of Computed Tomographic Perfusion Acquisitions in Neuroendocrine Liver Metastases and Normal Liver. J Comput Assist Tomogr 39(3):373-82, 2015. e-Pub 2015. PMID: 25626401.
95. Dasari A, Phan A, Gupta S, Rashid A, Yeung SC, Hess K, Chen H, Tarco E, Chen H, Wei C, Anh-Do K, Halperin DM, Meric-Bernstam F, Yao JC. Phase I study of cixutumumab with everolimus and octreotide LAR in advanced neuroendocrine carcinoma. Endocr Relat Cancer. e-Pub 2015. PMID: 25900182.
96. Oyeniyi J, Wu J, Liu D, Yao JC, Green H, Albritton K, Huh W, Hayes-Jordan A. Treatment of carcinomatosis using cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in adolescents and young adults. Am J Surg 209(4):610-5, 2015. e-Pub 2015. PMID: 25746912.
97. Lombard-Bohas C, Yao JC, Hobday T, Van Cutsem E, Wolin EM, Panneerselvam A, Stergiopoulos S, Shah MH, Capdevila J, Pommier R. Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-3 Trial. Pancreas 44(2):181-9, 2015. e-Pub 2015. PMID: 25479584.
98. Yao JC, Phan AT, Hess K, Fogelman D, Jacobs C, Dagohoy C, Leary C, Xie K, Ng CS. Perfusion Computed Tomography as Functional Biomarker in Randomized Run-In Study of Bevacizumab and Everolimus in Well-Differentiated Neuroendocrine Tumors. Pancreas 44(2):190-7, 2015. e-Pub 2015. PMID: 25426617.
99. Anthony LB, Pavel ME, Hainsworth JD, Kvols LK, Segal S, Hörsch D, Van Cutsem E, Öberg K, Yao JC. Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial. Neuroendocrinology. e-Pub 2015. PMID: 25824001.
100. Kulke MH, Shah MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw 13(1):78-108, 2015. e-Pub 2015. PMID: 25583772.
101. Kulke MH, O'Dorisio T, Phan A, Bergsland E, Law L, Banks P, Freiman J, Frazier K, Jackson J, Yao JC, Kvols L, Lapuerta P, Zambrowicz B, Fleming D, Sands A. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer 21(5):705-14, 2014. e-Pub 2014. PMID: 25012985.
102. Estrella JS, Ma LT, Milton DR, Yao JC, Wang H, Rashid A, Broaddus RR. Expression of estrogen-induced genes and estrogen receptor β in pancreatic neuroendocrine tumors: implications for targeted therapy. Pancreas 43(7):996-1002, 2014. e-Pub 2014. PMID: 25058880.
103. Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer 28:9, 2014. e-Pub 2014. PMID: 24771552.
104. Estrella JS, Broaddus RR, Mathews A, Milton DR, Yao JC, Wang H, Rashid A. Progesterone receptor and PTEN expression predict survival in patients with low- and intermediate-grade pancreatic neuroendocrine tumors. Arch Pathol Lab Med 138(8):1027-36, 2014. e-Pub 2014. PMID: 25076292.
105. Halperin DM, Phan AT, Hoff AO, Aaron M, Yao JC, Hoff PM. A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. BMC Cancer(14):561, 2014. e-Pub 2014. PMID: 25086465.
106. Shen C, Shih YC, Xu Y, Yao JC. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis. Cancer 120(13):2039-49, 2014. e-Pub 2014. PMID: 24676892.
107. Ng CS, Chandler AG, Yao JC, Herron DH, Anderson EF, Charnsangavej C, Hobbs BP. Effect of pre-enhancement set point on computed tomographic perfusion values in normal liver and metastases to the liver from neuroendocrine tumors. J Comput Assist Tomogr 38(4):526-34, 2014. e-Pub 2014. PMID: 24651739.
108. Chau I, Casciano R, Willet J, Wang X, Yao JC. Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review. Eur J Cancer Care (Engl) 22(6):714-25, 2013. e-Pub 2013. PMID: 23895457.
109. Ajani JA, Xiao L, Roth JA, Hofstetter WL, Walsh G, Komaki R, Liao Z, Rice DC, Vaporciyan AA, Maru DM, Lee JH, Bhutani MS, Eid A, Yao JC, Phan AP, Halpin A, Suzuki A, Taketa T, Thall PF, Swisher SG. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 24(11):2844-9, 2013. e-Pub 2013. PMID: 23975663.
110. Boyd AE, Deford LL, Mares JE, Leary CC, Garris JL, Dagohoy CG, Boving VG, Brook JP, Phan A, Yao JC. Improving the Success Rate of Gluteal Intramuscular Injections. Pancreas 42(5):878-82, 2013. e-Pub 2013. PMID: 23508015.
111. Abrams JS, Mooney MM, Zwiebel JA, Korn EL, Friedman SH, Finnigan SR, Schettino PR, Denicoff AM, Kruhm MG, Montello M, Misra RR, Ansher SS, DiPiazza KJ, Souhan EM, Wickerham DL, Giantonio BJ, O’Donnell RT, Sullivan DM, Soto NI, Fleming GF, Prindiville SA, Petryshyn RA, Hautala JA, Grad O, Zuckerman BL, Meyer RM, Yao JC, Baker LA, Buckner JC, Hortobagyi GN, Doroshow JH. Implementation of Timeline Reforms Speeds Initiation of National Cancer Institute–Sponsored Trials. JNCI 105(13):954-9, 2013. e-Pub 2013. PMID: 23776198.
112. Landry CS, Lin HY, Phan A, Charnsangavej C, Abdalla EK, Aloia T, Nicolas Vauthey J, Katz MH, Yao JC, Fleming JB. Resection of At-Risk Mesenteric Lymph Nodes Is Associated with Improved Survival in Patients with Small Bowel Neuroendocrine Tumors. World J Surg 37(7):1695-700, 2013. e-Pub 2013. PMID: 23657749.
113. Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC. Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors. Pancreas 42(4):557-577, 2013. e-Pub 2013. PMID: 23591432.
114. Yao JC, Lagunes DR, Kulke MH. Targeted Therapies in Neuroendocrine Tumors (NET): Clinical Trial Challenges and Lessons Learned. Oncologist 18(5):525-32, 2013. e-Pub 2013. PMID: 23615698.
115. Atiq M, Bhutani MS, Bektas M, Lee JE, Gong Y, Tamm EP, Shah CP, Ross WA, Yao JC, Raju GS, Wang X, Lee JH. EUS-FNA for Pancreatic Neuroendocrine Tumors: A Tertiary Cancer Center Experience. Dig Dis Sci 57(3):791-800, 2013. e-Pub 2013. PMID: 21964743.
116. Overman MJ, Modak J, Kopetz S, Murthy R, Yao JC, Hicks ME, Abbruzzese JL, Tam AL. Use of research biopsies in clinical trials: are risks and benefits adequately discussed?. J Clin Oncol 31(1):17-22, 2013. e-Pub 2013. PMID: 23129736.
117. Serra S, Zheng L, Hassan M, Phan AT, Woodhouse LJ, Yao JC, Ezzat S, Asa SL. The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy. Cancer Res 72(22):5683-91, 2012. e-Pub 2012. PMID: 22986737.
118. Hess GP, Chen CC, Liu Z, Yao JC, Phan AT, Hill JW. Clinical Burden of Illness in Patients With Neuroendocrine Tumors. Pancreas 41(7):1058-62, 2012. e-Pub 2012. PMID: 22513292.
119. Balachandran A, Tamm EP, Bhosale PR, Katz MH, Fleming JB, Yao JC, Charnsangavej C. Venous tumor thrombus in nonfunctional pancreatic neuroendocrine tumors. AJR Am J Roentgenol 199(3):602-8, 2012. e-Pub 2012. PMID: 22915400.
120. Kulke MH, ABrd B, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, BWnd K, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA. Neuroendocrine tumors. J Natl Compr Canc Netw 10(6):724-64, 2012. e-Pub 2012. PMID: 22679117.
121. Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas 41(3):461-6, 2012. e-Pub 2012. PMID: 22422138.
122. Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F, Gonzalez-Angulo AM, Rashid A, Crosby K, Dong M, Phan AT, Wolff RA, Gupta S, Mills GB, Yao J. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res 18(6):1777-89, 2012. e-Pub 2012. PMID: 22422409.
123. Yao JC, Phan AT. Optimising Therapeutic Options for Patients with Advanced Neuroendocrine Tumours. European Oncology and Haematology 8(4):217-23, 2012. e-Pub 2012.
124. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378(9808):2005-11, 2011. e-Pub 2011. PMID: 22119496.
125. Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, Cherfi A, Öberg KE. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab 96(12):3741-9, 2011. e-Pub 2011. PMID: 21994954.
126. Gaur P, Sceusi EL, Samuel S, Xia L, Fan F, Zhou Y, Lu J, Tozzi F, Lopez-Berestein G, Vivas-Mejia P, Rashid A, Fleming JB, Abdalla EK, Curley SA, Vauthey JN, Sood AK, Yao JC, Ellis LM. Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology 141(5):1728-37, 2011. e-Pub 2011. PMID: 21806944.
127. Yao JC, Phan AT. Overcoming antiangiogenic resistance. Clin Cancer Res 17(16):5217-9, 2011. e-Pub 2011. PMID: 21828238.
128. Kulke MH, Bendell J, Kvols L, Picus J, Pommier R, Yao J. Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol 4(1):29, 2011. e-Pub 2011. PMID: 21672194.
129. Salazar R, Reidy-Lagunes D, Yao J. Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer. Drugs 71(7):841-52, 2011. e-Pub 2011. PMID: 21568362.
130. Kulke M, Siu L, Tepper J, Fisher G, Jaffe D, Haller D, Ellis L, Benedetti J, Bergsland E, Hobday T, Van Cutsen E, Pingpank J, Oberg K, Cohen S, Posner M, Yao, JC. Future Directions in the Treatments of Neuroendocrine Tumors:Consensus Report of the National Cancer Institute Neuroendocrine Clinical Trials Planning Meeting. J Clin Oncol 29(7):934-43, 2011. e-Pub 2011. PMID: 21263089.
131. Lebwohl D, Thomas G, Lane HA, O'Reilly T, Escudier B, Yao JC, Pavel M, Franz D, Berg W, Baladi JF, Stewart J, Motzer RJ. Research and innovation in the development of everolimus for oncology. Expert Opin Drug Discov 6(3):323-38, 2011. e-Pub 2011. PMID: 22647206.
132. Capdevila J, Salazar R, Halperín I, Abad A, Yao JC. Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors. Cancer Metastasis Rev Suppl 1:27-34, 2011. e-Pub 2011. PMID: 21311955.
133. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 29(7):934-43, 2011. e-Pub 2011. PMID: 21263089.
134. Ng CS, Charnsangavej C, Wei W, Yao JC. Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy. AJR Am J Roentgenol 196(3):569-76, 2011. e-Pub 2011. PMID: 21343498.
135. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K, Tumors RAD, Study Group TT. Everolimus for Advanced Pancreatic Neuroendocrine Tumors. N Engl J Med 364(364(6)):514-23, 2011. e-Pub 2011. PMID: 21306238.
136. Walsh KM, Choi M, Oberg K, Kulke MH, Yao JC, Wu C, Jurkiewicz M, Hsu LI, Hooshmand SM, Hassan M, Janson ET, Cunningham JL, Vosburgh E, Sackler RS, Lifton RP, Dewan AT, Hoh J. A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum. Endocr Relat Cancer 18(1):171-80, 2011. e-Pub 2011. PMID: 21139019.
137. Walsh KM, Choi M, Oberg K, Kulke MH, Yao JC, Wu C, Jurkiewicz M, Hsu LI, Hooshmand SM, Hassan M, Janson ET, Cunningham JL, Vosburgh E, Sackler RS, Lifton RP, Dewan AT, Hoh J. A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum. Endocr Relat Cancer 18(1):171-80, 2011. e-Pub 2011. PMID: 21139019.
138. Yao JC, Catena L, Colao A, Paganelli G. Perspectives in the development of novel treatment approaches. Tumori 96(5):858-73, 2010. e-Pub 2010. PMID: 21302643.
139. Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, Nutting C, Bushnell DL, Caplin ME, Yao JC, Tumor Society NAN. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas 39(6):753-66, 2010. e-Pub 2010. PMID: 20664473.
140. Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier RF, Yao JC, Jensen RT, Tumor Society NAN. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 39(6):735-52, 2010. e-Pub 2010. PMID: 20664472.
141. Gaur P, Leary C, Yao JC. Thymic neuroendocrine tumors: a SEER database analysis of 160 patients. Ann Surg 251(6):1117-21, 2010. e-Pub 2010. PMID: 20485130.
142. Ajani JA, Correa AM, Walsh GL, Komaki R, Lee JH, Vaporciyan AA, Rice DC, Yao JC, Maru DM, Hofstetter WL, Phan AT, Swisher SG. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer 116(7):1656-63, 2010. e-Pub 2010. PMID: 20143431.
143. Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gönen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, Moran C, Moss SF, Oberg K, O'Toole D, Rindi G, Robert ME, Suster S, Tang LH, Tzen CY, Washington MK, Wiedenmann B, Yao JC. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol 34(8):1228-30, 2010. e-Pub 2010. PMID: 20523210.
144. Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, Ho L, Ajani J, Phan A. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer 116(6):1446-53, 2010. e-Pub 2010. PMID: 20108336.
145. Jia Z, Gao Y, Wang L, Li Q, Zhang J, Le X, Wei D, Yao JC, Chang DZ, Huang S, Xie K. Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity. Cancer Res 70(3):1111-9, 2010. e-Pub 2010. PMID: 20086170.
146. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial. J Clin Oncol 28(1):69-76, 2010. e-Pub 2010. PMID: 19933912.
147. Clark OH, Ajani JA, ABrd B, Berlin JD, Blaszkowsky LS, Byrd D, Choti MA, Doherty GM, Engstrom PF, Gibbs JF, Heslin MJ, Kandeel F, Kessinger A, Kulke MH, Kunz P, Kvols L, Jr OJ, Ratliff TW, Salem R, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, Yao JC. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine Tumors. J Natl Compr Canc Netw 7(7):712, 2009. e-Pub 2009. PMID: 19635226.
148. Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, Jia Z, Li Q, Yao JC, Xie K. Overexpression of Phosphorylated Mammalian Target of Rapamycin Predicts Lymph Node Metastasis and Prognosis of Chinese Patients with Gastric Cancer. Clin Cancer Res 15(5):1078-0432, 2009. e-Pub 2009. PMID: 19223493.
149. Badgwell B, Cormier JN, Xing Y, Yao JC, Bose D, Krishnan S, Pisters P, Feig B, Mansfield P. Attempted salvage resection for recurrent gastric or gastroesophageal cancer. Ann Surg Oncol 16(4):1074-1076, 2009. e-Pub 2009. PMID: 18985270.
150. Wang L, Guan X, Zhang J, Jia Z, Wei D, Li Q, Yao J, Xie K. Targeted inhibition of Sp1-mediated transcription for antiangiogenic therapy of metastatic human gastric cancer in orthotopic nude mouse models. Int J Oncol 33(1):161-7, 2008. e-Pub 2008. PMID: 18575762.
151. Phan AT, Yao JC. Neuroendocrine tumors: novel approaches in the age of targeted therapy. Oncology 22(14):1617-23, 2008. e-Pub 2008. PMID: 19198220.
152. Truong CD, Li W, Feng W, Cagle P, Khoury T, Alrawi S, Xie K, Yao J, Tan D. Alpha-Methylacyl-CoA Racemase Expression is Upregulated in Gastric Adenocarcinoma: A Study of 249 Cases. Int J Clin Exp Pathol 1(6):518-523, 2008. e-Pub 2008. PMID: 18787636.
153. Scott LC, Yao JC, ABrd B, Thomas AL, Falk S, Mena RR, Picus J, Wright J, Mulcahy MF, Ajani JA, Evans TR. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Chemother Pharmacol 63(2):363-70, 2008. e-Pub 2008. PMID: 18398613.
154. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess KR, Gupta S, Jacobs C, Mares J, Landgraf A, Rashid A, Meric-Bernstam F. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study. J Clin Oncol 26(26):4311-4318, 2008. e-Pub 2008. PMID: 18779618.
155. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdallas E, Fleming JB, Vauthey JN, Rashid A, Evans DB. One Hundred Years After Carcinoid: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. J Clin Oncol 26(18), 2008. e-Pub 2008. PMID: 18565894.
156. Hassan MM, Phan A, Li D, Dagohoy, CG, Leary C, Yao JC. Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study. Cancer Epidemiology Biomarkers Prev 17(4):959-65, 2008. e-Pub 2008.
157. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 15(1):257-66, 2008. e-Pub 2008.
158. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26(8):1316-23, 2008. e-Pub 2008. PMID: 18323556.
159. Murthy R, Kamat P, Nunez R, Madoff DC, Gupta S, Salem R, Yao JC. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol 19(1):145-51, 2008. e-Pub 2008.
160. Kin do H, Nagano Y, Choi IS, White JA, Yao JC, Rashid A. Allelic alterations in well-differentiated neuroendocrine tumors (carcinoid tumors) identified by genome-wide single nucleotide polymorphism analysis and comparison with pancreatic endocrine tumors. Genes Chromosomes Cancer 47(1):84-92, 2008. e-Pub 2008. PMID: 17943967.
161. Feng W, Brown RE, Trung CD, Li W, Wang L, Khoury T, Alrawi S, Yao J, Xia K, Tan D. Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma. Ann Clin Lab Sci 38:195-209, 2008. e-Pub 2008. PMID: 18715846.
162. Yao JC, Eisner M, Leary C, Dagohoy C, Phan A, Rahid A, Hassan M, Evans D. Population based study of islet cell carcinoma. Ann Surg Oncol 14(12):3492-500, 2007. e-Pub 2007.
163. Patel PR, Yao JC, Hess K, Schnirer I, Rashid A, Ajani JA. Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. Cancer 110(10):2186-90, 2007. e-Pub 2007.
164. Braiteh F, Yao J. Electronic Clinical Challenges and Images in GI. Gastroenterology 133(4):e1-2, 2007. e-Pub 2007.
165. Gnd VB, Rashid A, Yang AD, Abdalla EK, Gray MJ, Liu W, Somcio R, Fan F, Camp ER, Yao JC, Ellis LM. The development and characterization of a human midgut carcinoid cell line. Clinical Cancer Research 13(16):4704-12, 2007. e-Pub 2007.
166. Choi I, Estecio M, Nagano Y, Kim DH, White JA, Yao JC, Issa JP, Rashid A. Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors). Modern Pathology 20(7):802-10, 2007. e-Pub 2007.
167. Nagano Y, Kim do H, Zhang L, White JA, Yao JC, Hamilton SR, Rashid A. Allelic Alterations in Pancreatic Endocrine Tumors Identified by Genome-Wide Single Nucleotide Polymorphism Analysis. Endocrine Related Cancer 14(2):483-92, 2007. e-Pub 2007.
168. Jia Z, Zhang J, Wei D, Wang L, Yuan P, Le X, Li Q, Yao JC, Xie K. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin. Cancer Res 67(10):4878-85, 2007. e-Pub 2007.
169. Zhang JX, Jia Z, Li Q, Wang L, Rashid A, Zhu Z, Evans DB, Vauthey JN, Xie K, Yao JC. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression free survival among patients with low-grade neuroendocrine tumors. Cancer 109(8):1478-86, 2007. e-Pub 2007.
170. Yao JC. Neuroendocrine tumors. Molecular targeted therapy for carcinoic and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab 21(1):163-72, 2007. e-Pub 2007.
171. Wang LW, Li Q, Hua ZL, Zhou F, Xie K, Wei D, Yao JC, Ajani J. Expression of transcription factor Sp1 in human gastric cancer tissue and its correlation with prognosis. Zhonghua Zhong Liu Za Zhi 29(2):107-11, 2007. e-Pub 2007.
172. Nilsson O, Van Cutsem E, Gianfranco DF, Yao JC, Pavel ME, McNicol AM, Sevilla Garcia MI, Knapp WH, Keletimur F, Sauvanet A, Pauwels S, Kwekkeboom DJ, Caplin M. Poorly Differentiated Carcinomas of the Foregut (Gastric, Duodenal and Pancreatic). Neuroendocrinology 84(3):212-5, 2007. e-Pub 2007.
173. Lenz HJ, Lee FC, Haller DG, Singh D, Benson AB, rd, Strumberg D, Yanagihara R, Yao JC, Phan AT, Ajani JA. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phas II study. Cancer 109(1):33-40, 2007. e-Pub 2007.
174. Yao JC, Zhang JX, Rashid A, Yeung SC, Szklaruk J, Hess K, Xie K, Ellis L, Abbruzzese JL, Ajani JA. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res 13(1):234-40, 2007. e-Pub 2007. PMID: 17200360.
175. Duran I, Salazar R, Casanovas O, Arrazubi V, Vilar E, Siu L, Yao J, Tabernero J. New drug development in digestive neuroendocrine tumors. Ann Oncol 18(8):1307-13, 2007. e-Pub 2007.
176. Zhang J, Jiang Y, Jia Z, Li Q, Gong W, Wang L, Wei D, Yao J, Fang S, Xie K. Association of elevated GRP78 expression with increased lymph node metastasis and poor prognosis in patients with gastric cancer. Clin Exp Metastasis 23(7-8):401-10, 2007. e-Pub 2007. PMID: 17187227.
177. Rohatgi PR, Yao JC, Hess K, Schnirer I, Rashid A, Mansfield PF, Pisters PW, Ajani JA. Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival. Cancer 107(11):2576-80, 2006. e-Pub 2006. PMID: 17075877.
178. Kanai M, Wei D, Li Q, Jia Z, Ajani J, Le X, Yao JC, Xie K. Loss of Kruppel-like factor 4 expression contributes to Sp1 overexpression and human gastric cancer development and progression. Clin Cancer Res 12(21):6395-402, 2006. e-Pub 2006. PMID: 17085651.
179. Madoff DC, Gupta S, Ahrar K, Murthy R, Yao JC. Update on the Management of Neuroendocrine hepatic Metastases. J Vasc Interv Radiol 17(8):1235-49; quiz 1250, 2006. e-Pub 2006. PMID: 16923972.
180. Ajani JA, Jiang Y, Faust J, Chang BB, Ho L, Yao JC, Rousey S, Dakhil S, Cherny RC, Craig C, Bleyer A. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs 24(4):353-7, 2006. e-Pub 2006. PMID: 16683077.
181. Kouvaraki MA, Shapiro SE, Cote GJ, Lee JE, Yao JC, Waguespack SG, Gagel RF, Evans DB, Perrier ND. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg 30(5):643-53, 2006. e-Pub 2006. PMID: 16680581.
182. Ajani JA, Lee FC, Singh DA, Haller DG, Lenz HJ, Benson AB, rd, Yanagihara R, Phan AT, Yao JC, Strumberg D. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24(4):663-7, 2006. e-Pub 2006. PMID: 16446338.
183. Liu L, Broaddus RR, Yao JC, Xie S, White JA, Wu TT, Hamilton SR, Rashid A. Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis. Mod Pathol 18(12):1632-40, 2005. e-Pub 2005. PMID: 16258509.
184. Mullen JT, Wang H, Yao JC, Lee JH, Perrier ND, Pisters PW, Lee JE, Evans DB. Carcinoid tumors of the duodenum. Surgery 138(6):971-7, 2005. e-Pub 2005. PMID: 16360380.
185. Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, Hicks ME, Rao S, Vauthey JN, Ajani JA, Yao JC. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104(8):1590-602, 2005. e-Pub 2005. PMID: 16134179.
186. Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M, Urrea P. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 23(28):6957-65, 2005. e-Pub 2005. PMID: 16145066.
187. Wang GG, Yao JC, Worah S, White JA, Luna R, Wu TT, Hamilton SR, Rashid A. Comparison of genetic alterations in neuroendocrine tumors: frequent loss of chromosome 18 in ileal carcinoid tumors. Mod Pathol 18(8):1079-87, 2005. e-Pub 2005. PMID: 15920555.
188. Wei D, Gong W, Oh SC, Li Q, Kim WD, Wang L, Le X, Y, Yao JC, Wu TT, Huang S, Xie K. Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Res 65(11):4809-16, 2005. e-Pub 2005. PMID: 15930301.
189. Yao JC, Tseng JF, Worah S, Hess KR, Mansfield PF, Crane CH, Schnirer, II, Reddy S, Chiang SS, Najam A, Yu C, Giacco GG, Xie K, Wu TT, Feig BW, Pisters PW, Ajani JA. Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol 23(13):3094-103, 2005. e-Pub 2005. PMID: 15860869.
190. Wei D, Gong W, Kanai M, Schlunk C, Wang L, Yao JC, Wu TT, Huang S, Xie K. Drastic down-regulation of Kruppel-like factor 4 expression is critical in human gastric cancer development and progression. Cancer Res 65(7):2746-54, 2005. e-Pub 2005. PMID: 15805274.
191. Zhang Z, Liao Z, Jin J, Ajani J, Chang JY, Jeter M, Guerrero T, Stevens CW, Swisher S, Ho L, Yao JC, Allen P, Cox JD, Komaki R. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 61(3):656-64, 2005. e-Pub 2005. PMID: 15708243.
192. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, Janjan N, Feig B, Faust J, Yao JC, Nivers R, Morris J, Pisters PW. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 23(6):1237-44, 2005. e-Pub 2005. PMID: 15718321.
193. Gong W, Wang L, Yao JC, Ajani JA, Wei D, Aldape KD, Xie K, Sawaya R, Huang S. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res 11(4):1386-93, 2005. e-Pub 2005. PMID: 15746037.
194. An C, Choi IS, Yao JC, Worah S, Xie K, Mansfield PF, Ajani JA, Rashid A, Hamilton SR, Wu TT. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res 11(2 Pt 1):656-63, 2005. e-Pub 2005. PMID: 15701853.
195. Gong W, Jiang Y, Wang L, Wei D, Yao JC, Huang S, Fang S, Xie K. Expression of autocrine motility factor correlates with the angiogenic phenotype of and poor prognosis for human gastric cancer. Clin Cancer Res 11:5778-83, 2005. e-Pub 2005.
196. Wang L, Shi GG, Yao JC, Gong W, Wei D, Wu TT, Ajani JA, Huang S, Xie K. Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer. Gastric Cancer 8(1):18-28, 2005. e-Pub 2005. PMID: 15747170.
197. Wang L, Guan X, Gong W, Yao JC, Peng Z, Wei D, Wu TT, Huang S, Xie K. Altered Expression of Transcription Factor Sp1 Critically Impacts the Angiogenic Phenotype of Human Gastric Cancer. Clin Exp Metastasis 22:205-213, 2005. e-Pub 2005.
198. Liao Z, Zhang Z, Jin J, Ajani JA, Swisher SG, Stevens CW, Ho L, Smythe R, Vaporciyan AA, Putnam JB, Jr, Walsh GL, Roth JA, Yao JC, Allen PK, Cox JD, Komaki R. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys 60(5):1484-93, 2004. e-Pub 2004. PMID: 15590179.
199. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22(23):4762-71, 2004. e-Pub 2004. PMID: 15570077.
200. Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J, Jr, Walsh G, Smythe R, Roth J, Yao JC, Allen P, Cox JD, Komaki R. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 60(2):427-36, 2004. e-Pub 2004. PMID: 15380576.
201. Agarwal B, Swisher S, Ajani J, Kelly K, Fanning C, Komaki RR, Putnam JB, Jr, Abu-Hamda E, Molke KL, Walsh GL, Correa AM, Ho L, Liao Z, Lynch PM, Rice DC, Smythe WR, Stevens CW, Vaporciyan AA, Yao JC, Roth JA. Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. Am J Gastroenterol 99:1258-66, 2004. e-Pub 2004. PMID: 15233663.
202. Yao JC, Wang L, Wei D, Gong W, Hassan M, Wu TT, Mansfield P, Ajani J, Xie K. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 10(12 Pt 1):4109-17, 2004. e-Pub 2004. PMID: 15217947.
203. Yang Q, Cleary KR, Yao JC, Swisher SG, Roth JA, Lynch PM, Komaki R, Ajani JA, Rashid A, Hamilton SR, Wu TT. Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. Dis Esophagus 17(1):38-43, 2004. e-Pub 2004. PMID: 15209739.
204. Jiang Y, Wang L, Gong W, Wei D, Le X, Yao JC, Ajani J, Abbruzzese JL, Huang S, Xie K. A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clinc Exp Metastasis 21:755-64, 2004. e-Pub 2004.
205. Wang L, Wei D, Huang S, Peng Z, Le X, Wu TT, Yao JC, Ajani J, Xie K. Unique Patterns of Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 9:6371-80, 2003. e-Pub 2003. PMID: 14695137.
206. Ajani JA, Faust J, Yao JC, Komaki R, Stevens C, Swisher S, Putnam JB, Vaporciyan A, Smythe R, Walsh G, Rice D, Roth J. Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Oncology (Williston Park) 17(9 Suppl 8):20-2, 2003. e-Pub 2003. PMID: 14569843.
207. Gupta S, Yao JC, Ahrar K, Wallace MJ, Morello FA, Madoff DC, Murthy R, Hicks ME, Ajani JA. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 9(4):261-7, 2003. e-Pub 2003. PMID: 12967136.
208. Yao JC, Schnirer, II, Reddy S, Chiang S, Najam A, Yu C, Giacco G, Hess K, Rashid A, Xie K, Lynch P, Ajani JA. Effects of Gender, Race, and Ethnicity on the Pattern of Gastric Cancer Localization. Gastric Cancer 5:208-12, 2002. e-Pub 2002. PMID: 12491078.
209. Schnirer, II, Komaki R, Yao JC, Swisher S, Putnam J, Pisters PW, Roth JA, Ajani JA. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol 24(1):91-5, 2001. e-Pub 2001. PMID: 11232959.
210. Yao JC, Ajani JA. Gastric Cancer. Curr Opin Gastroenterol 16(6):516-21, 2000. e-Pub 2000. PMID: 17031130.
211. Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov 11(11):2738-2747. PMID: 34261675.
212. Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP, investigators N. Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 22(12):1752-1763. PMID: 34793718.
213. Kaseb AO, Kappadath SC, Lee SS, Raghav KP, Mohamed YI, Xiao L, Morris JS, Ohaji C, Avritscher R, Odisio BC, Kuban J, Abdelsalam ME, Chasen B, Elsayes KM, Elbanan M, Wolff RA, Yao JC, Mahvash A. A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90 Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. J Hepatocell Carcinoma 8:1129-1145. PMID: 34527608.
214. Pan IW, Halperin DM, Kim B, Yao JC, Shih YT. A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome. Pharmacoeconomics 39(11):1271-1297. PMID: 34378163.

Invited Articles

1. Halperin DM, Kulke MH, Yao JC. A Tale of Two Tumors: Treating Pancreatic and Extrapancreatic Neuroendocrine Tumors. Annu Rev Med 66:1-16, 2015. e-Pub 2015. PMID: 25341008.
2. Dasari A, Yao JC. Gastrointestinal neuroendocrine tumors: slow but steady progress. Oncology, 2014. e-Pub 2014. PMID: 25224473.
3. Lewis MA, Yao JC. Molecular pathology and genetics of gastrointestinal neuroendocrine tumours. Curr Opin Endocrinol Diabetes Obes 1:22-7, 2014. e-Pub 2014. PMID: 24310147.
4. Yao JC, Meric-Bernstam F, Lee JJ, Eckhardt SG. Accelerated Approval and Breakthrough Therapy Designation: Oncology Drug Development on Speed?. Clin Cancer Res 19(16):4305-4308, 2013. e-Pub 2013. PMID: 23833307.
5. Metz DC, Choi J, Strosberg J, Heaney AP, Howden CW, Klimstra D, Yao JC. A rationale for multidisciplinary care in treating neuroendocrine tumours. Curr Opin Endocrinol Diabetes Obes 19(4):306-313, 2012. e-Pub 2012. PMID: 22760514.
6. Dong M, Phan AT, Yao JC. New strategies for advanced neuroendocrine tumors in the era of targeted therapy. Clin Cancer Res 18(7):1830-6, 2012. e-Pub 2012. PMID: 22338018.
7. Dong M, Yao JC. mTOR inhibition, a potential novel approach for bronchial carcinoids. Endocr Relat Cancer 18(3):15-8, 2011. e-Pub 2011. PMID: 21427170.
8. Yao JC, Hoff PM. Molecular targeted therapy for neuroendocrine tumors. Hematol Oncol Clin North Am 21(3):575-81, 2007. e-Pub 2007. PMID: 17548041.
9. Yao JC. Molecular Targeted Therapy for Carcinoid and Islet Cell Carcinoma. Best Practice & Research Clinical Endocrinology & Metabolism(21):163-172, 2007. e-Pub 2007.
10. Yao JC. Meta-analysis of Published Data on Nonoperative Approaches to Esophageal Cancer Flawed Because of Heterogeneity, Other Factors. Abstracts in Hematology & Oncology 7:3-4, 2004. e-Pub 2004.
11. Yao JC, Vauthey JN. Primary and metastatic hepatic carcinoid: is there an algorithm?. Ann Surg Oncol 10(10):1133-5, 2003. e-Pub 2003. PMID: 14654466.
12. Yao JC, Mansfield PF, Pisters PW, Feig BW, Janjan NA, Crane C, Ajani JA. Combined-modality therapy for gastric cancer. Semin Surg Oncol 21(4):223-7, 2003. e-Pub 2003. PMID: 14648779.
13. Yao JC, Ajani JA. Adjuvant and preoperative chemotherapy for gastric cancer. Curr Oncol Rep 4(3):222-8, 2002. e-Pub 2002. PMID: 11937012.
14. Yao JC, Ajani JA. Therapy of localized gastric cancer: preoperative and postoperative approaches. Ann Oncol 13 Suppl 4:7-12, 2002. e-Pub 2002. PMID: 12401660.
15. Ajani JA, Yao JC. Preoperative therapy for local-regional gastric cancer: rationale and review of trials. Gan To Kagaku Ryoho 27 Suppl 2:392-4, 2000. e-Pub 2000. PMID: 10895184.
16. Yao, JC, Ajani JA. Current strategies for treatment of gastric cancer. Current Opinion in Gastroenterology 16(6):516-21, 2000. e-Pub 2000.

Other Articles

1. Yousef M, Hurd MW, Yousef A, Ludmir EB, Pillai AB, Peterson J, Koay EJ, Albarouki S, Tzeng CW, Snyder R, Katz MHG, Wang H, Overman MJ, Maitra A, Pant S, Smaglo BG, Wolff RA, Yao JC, Shen JP, Zhao D Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. Oncologist 30(1), 2025. PMID: 39014543.
2. Kiyasu Y, Zuo X, Liu Y, Yao JC, Shureiqi I EPA, DHA, and resolvin effects on cancer risk: The underexplored mechanisms. Prostaglandins Other Lipid Mediat 174:106854, 2024. PMID: 38825147.
3. Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel M DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist 27(11):940-951, 2022. PMID: 35983951.
4. Hicks RJ, Dromain C, de Herder WW, Costa FP, Deroose CM, Frilling A, Koumarianou A, Krenning EP, Raymond E, Bodei L, Sorbye H, Welin S, Wiedenmann B, Wild D, Howe JR, Yao J, O'Toole D, Sundin A, Prasad V ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. J Neuroendocrinol 34(3):e13040, 2022. PMID: 34668262.
5. Pan IW, Halperin DM, Kim B, Yao JC, Shih YT A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome. Pharmacoeconomics 39(11):1271-1297, 2021. PMID: 34378163.
6. Ambrosini, V, Kunikowska, J, Baudin, E, Bodei, L, Bouvier, C, Capdevila, J, Cremonesi, M, De Herder, WW, Dromain, C, Falconi, M, Fani, M, Fanti, S, Hicks, RJ, Kabasakal, L, Kaltsas, G, Lewington, V, Minozzi, S, Cinquini, M, Öberg, K, Oyen, W, O'Toole, D, Pavel, M, Ruszniewski, P, Scarpa, A, Strosberg, JR, Sundin, A, Taïeb, D, Virgolini, I, Wild, D, Herrmann, K, Yao, JC Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. European Journal of Cancer 146:56-73, 2021. PMID: 33588146.
7. Tetzlaff MT, Tang S, Duke T, Grabell DA, Cabanillas ME, Zuo Z, Yao JC, Nagarajan P, Aung PP, Torres-Cabala CA, Duvic M, Prieto VG, Huen A, Curry JL Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis fungoides-like morphologic and molecular features. J Cutan Pathol 46(11):872-877, 2019. PMID: 31254410.
8. Balanescu DV, Donisan T, Lopez-Mattei J, Hassan S, Kim P, Dasari A, Halperin D, Yao JC, Kar B, Gregoric I, Balanescu SM, Iliescu C The 1, 2, 3, 4 of carcinoid heart disease: Comprehensive cardiovascular imaging is the mainstay of complex surgical treatment. Oncol Lett 17(5):4126-4132, 2019. PMID: 30944605.
9. Halperin DM, Yao JC Clinical Trial Design in Neuroendocrine Tumors. Hematol Oncol Clin North Am 30(1):209-17, 2016. PMID: 26614378.
10. Yao JC, Phan AT, Jehl V, Shah G, Meric-Bernstam F Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience. Cancer Res 73(5):1449-53, 2013. PMID: 23436795.
11. Kouvaraki MA, Solorzano CC, Shapiro SE, Yao JC, Perrier ND, Lee JE, Evans DB Surgical treatment of non-functioning pancreatic islet cell tumors. J Surg Oncol 89(3):170-85, 2005. PMID: 15719379.
12. Xiong HQ, Gunderson LL, Yao JC, Ajani JA Chemoradiation for resectable gastric cancer. Lancet Oncol 4(8):498-505, 2003. PMID: 12901965.
13. Lisenko Y, Kumar AJ, Yao JC, Ajani J, Ho L Leptomeningeal carcinomatosis originating from gastric cancer: report of eight cases and review of the literature. Am J Clin Oncol 26(2):165-70, 2003. PMID: 12714889.
14. Schnirer, II, Yao JC, Ajani JA Carcinoid--a comprehensive review. Acta Oncol 42(7):672-92, 2003. PMID: 14690153.
15. Yao JC, Shimada K, Ajani JA Adjuvant therapy for gastric carcinoma: closing out the century. Oncology (Williston Park) 13(11):1485-94; discussion 1497-502 passim, 1999. PMID: 10581599.
16. Yao JC, Thomakos N, McLaughlin P, Buchholz TA, Kudelka AP Tamoxifen-induced thrombocytopenia. Am J Clin Oncol 22(5):529-32, 1999. PMID: 10521073.

Editorials

1. Yao Y, Shen Y, Yao JC, Zuo X. Editorial: New advancement in tumor microenvironment remodeling and cancer therapy. Front Cell Dev Biol 12:1384567, 2024. PMID: 38516127.
2. Yao JC. Meta-analysis of Published Data on Nonoperative Approaches to Esophageal Cancer Flawed Because of Heterogeneity, Other Factors. Abstracts in Hematology & Oncology(7):3-4, 2004.

Abstracts

1. Xiao H, Sun XX, Sun CH, Wang EL, Wang XZ, Yao JC. [Therapeutic effect and mechanism of Jingfang Granules on acute lung injury based on intestinal flora and fecal metabolomics]. Zhongguo Zhong Yao Za Zhi 49(7):1915-1923, 2024. e-Pub 2024. PMID: 38812204.
2. Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, García-Alfonso P, Kocsis J, Gracian AC, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csőszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Cutsem EV, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Tabernero† J, Eng† C. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet 23, 2023. e-Pub 2023.
3. Hao DD, Lu ZH, Luo YG, Tu PF, Sun CH, Yao JC, Wu Q, Zhu ZX. [Potentiating effect and mechanism of extract of Jingfang Granules on activation of macrophages]. Zhongguo Zhong Yao Za Zhi 48(10):2803-2809, 2023. e-Pub 2023. PMID: 37282940.
4. Zhao MM, Yao L, Yao JC, Sun CH, Zhang GM, Zeng KW. [Anti-infectious pneumonia target discovery and molecular mechanism study of Jingfang Granules]. Zhongguo Zhong Yao Za Zhi 48(3):789-796, 2023. e-Pub 2023. PMID: 36872243.
5. Yang Z, Zhuo FF, Zhang GM, Sun CH, Tu PF, Yao JC, Zeng KW. [Anti-depression targets and mechanism study of Kaixin San]. Zhongguo Zhong Yao Za Zhi 48(2):472-480, 2023. e-Pub 2023. PMID: 36725237.
6. Abugabal YI, Kaseb AO, Abdel-Wahab R, Lacin S, Pestana RC, Wolff RA, Yao JC, Hassan M. Evaluating clinical and prognostic implications of Collagen IV in hepatocellular carcinoma. 2018 ASCO Annual Meeting, 2018. e-Pub 2018.
7. Abugabal YI, Hassan M, Abdel-Wahab R, Lacin S, Pestana RC, Wolff RA, Yao JC, Kaseb AO. Utility of Neuropilin-1 in predicting survival in patients with hepatocellular carcinoma. 2018 ASCO Annual Meeting, 2018. e-Pub 2018.
8. Halperin DM, Lee JJ, Yao JC. Predictive value of phase II clinical trials in pancreatic cancer: Rethinking the road to progress. 2013 ASCO Annual Meeting(J Clin Oncol), 2013. e-Pub 2013.
9. Yao JC. Prediction of prognosis in patients treated with everolimus for extrapancreatic neuroendocrine tumors by a single nucleotide polymorphism in PHLPP2. 2013 GI ASCO(J Clin Oncol), 2012. e-Pub 2012.
10. Shih YT, Xu Y, Leary C, Yao JC. Factors associated with octreotide LAR use among elderly patients with carcinoid syndrome: A population-based analysis. 2012 ASCO Annual Meeting(J Clin Oncol), 2012. e-Pub 2012.
11. Zornosa CC, Choti MA, Bobiak S, Kulke M, Yao JC, Bergsland EK, Nakakura EK, Bloomston M, Benson AB, Shah MH, Strosberg JR. Baseline demographics of neuroendocrine tumor patients presenting to seven National Comprehensive Cancer Network (NCCN) institutions: Development of a multi-institutional outcomes database. 2012 ASCO Annual Meeting(J Clin Oncol), 2012. e-Pub 2012.
12. Xu Y, Shih YT, Leary C, Shen C, Yao JC. Dosing patterns of octreotide LAR among elderly patients with neuroendocrine tumors: Analysis of the SEER-Medicare database. 2012 ASCO Annual Meeting(J Clin Oncol), 2012. e-Pub 2012.
13. Shen C, Xu Y, Yao JC, Shih YT. Octreotide LAR use among elderly patients with carcinoid syndrome and survival outcomes: A population-based analysis. 2013 GI ASCO(J Clin Oncol), 2012. e-Pub 2012.
14. Bobiak S, Choti MA, Benson AB, Strosberg JR, Bloomston M, Bergsland EK, Zornosa CC, Kulke M, Nakakura EK, Shah MH, Yao JC. Description of initial treatment for newly diagnosed metastatic carcinoid (cNET) and pancreatic neuroendocrine (pNET) patients. 2012 ASCO Annual Meeting(J Clin Oncol), 2012. e-Pub 2012.
15. Yao JC, Hainsworth JD, Wolin EM, Pavel ME, Baudin E, Gross D, Ruszniewski P, Tomassetti P, Panneerselvam A, Saletan S, Klimovsky J. Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET). 2012 ASCO Annual Meeting(J Clin Oncol), 2012. e-Pub 2012.
16. Yao JC, Hainsworth JD, Wolin EM, Pavel ME, Baudin E, Gross D, Ruszniewski P, Tomassetti P, Panneerselvam A, Saletan S, Klimovsky J. Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET). 2012 GI ASCO(J Clin Oncol), 2012. e-Pub 2012.
17. Lombard-Bohas C, Yao JC, Hobday TJ, Van Cutsem E, Wolin EM, Panneerselvam A, Castellana R, Stergiopoulos SG, Shah GD, Shah MH, Pommier RF. Efficacy and safety of everolimus in patients with advanced low- or intermediate-grade pancreatic neuroendocrine tumors previously treated with chemotherapy: Radiant-3 subgroup analysis. 2013 GI ASCO(J Clin Oncol), 2012. e-Pub 2012.
18. Choti MA, Mayorga MA, Bobiak S, Kulke M, Yao JC, Bergsland EK, Nakakura EK, Bloomston M, Benson AB, Shah MH, Strosberg JR. Baseline demographics of patients with neuroendocrine tumors presenting to seven National Comprehensive Cancer Network (NCCN) institutions: Development of a multi-institutional outcomes database. 2012 GI ASCO(J Clin Oncol), 2012. e-Pub 2012.
19. Dong M, Sangai T, Zhao Q, Rashid A, Meric-Bernstam F, Yao JC. Activation of hedgehog pathway in neuroendocrine tumors. 2013 GI ASCO(J Clin Oncol), 2012. e-Pub 2012.
20. Yao, JC. Effect of Everolimus Treatment on Markers of Angiogenesis in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET): Results From the Phase III RADIANT-3 Study. 2011 European Multidisciplinary Cancer Congress, 2011. e-Pub 2011.
21. Yao JC, Hainsworth JD, Baudin E, Peeters M, Hoersch D, Anthony LB, Klimovsky J, Grouss K, Jehl V, Pavel M. Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced. ASCO 2011 Annual Meeting, 2011. e-Pub 2011.
22. Yao, JC. Novel Study Design Using Perfusion CT as Functional Biomarker in Neuroendocrine Tumors. Anti Angiogenesis Conference 2011, 2011. e-Pub 2011.
23. Yao JC, Shah MH, Ito T, Lombard-Bohas C, Wolin EM, Van Cutsem E, Sachs C, Hoosen S, Lincy J, Hobday T. A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Tumors (PNET) (RADIANT-3). European Society for Medical Oncology (ESMO) Congress 2011, 2010. e-Pub 2010.
24. Pavel M, Hainsworth JD, Baudin E, Peeters M, Hoersch D, Anthony L, Hoosen S, St Peter J, Jehl V, Yao JC. A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial of Everolimus 1 Octreotide LAR vs. Placebo 1 Octreotide LAR in Patients with Advanced Neuroendocrine Tumors (NET) (RADIANT-2). European Society of Medical Oncology (ESMO) Congress 2011, 2010. e-Pub 2010.
25. Stern L, Arora S, Willet J, Wang X, Liu Z, Yao JC. A Systematic Review of Epidemiology, Treatment Pattern, Economic and Humanistic Studies in Advanced Neuroendocrine Tumors. European Society of Medical Oncology (ESMO) Congress 2010, 2010. e-Pub 2010.
26. Yao JC, Beaumont JL, Cella D, Choi S, Liu Z, Phan AT. Characteristics Associated with Health-Related Quality of Life of Patients with Neuroendocrine Tumor (NET). European Society of Medical Oncology (ESMO) Congress 2010, 2010. e-Pub 2010.
27. O¨ berg K, Kulke M, Pavel M, Phan AT, Hoosen S, St Peter J, Cherfi A, Yao JC. Prognostic and Predictive Value of Chromogranin A and Neuron-specific Enolase in Patients (PTS) with Advanced Pancreatic Neuroendocrine Tumors (PNET) Treated with Everolimus. European Society of Medical Oncology (ESMO) Congress 2010, 2010. e-Pub 2010.
28. Mani MA, Shroff RT, Jacobs CB, Wolff RA, Ajani JA, Yao JC, Phan AT. A phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma. Journal of Clinical Oncology, 2008 ASCO Annual Meeting 26, 2008. e-Pub 2008.
29. Moreno A, Akcakanat A, Munsell M, Soni A, Yao J, Meric-Bernstam F. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Molecular Targets and Cancer Therapeutics, AACR-NCI-EORTC International Conference, 2007. e-Pub 2007.
30. Zhang J, Jia Z, Wang L, Li Q, Xiangdong L, Xie K, Yao JC. Treatment with bevacizumab (BEV) upregulates expression of the transcription factor Sp1 and its downstream target genes in human carcinoid cells: Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A (MIT). Journal of Clinical Oncology, 2007 ASCO Annual Meeting 25(18S), 2007. e-Pub 2007.
31. Xie K, Jia Z, Zhang J, Wang L, Li Q, Le X, Yao J. Preferential inhibition of Sp1 expression in growing tumors by mithramycin-A (MIT) directly correlates with its potent antiangiogenic effects in human carcinoid xenograft model. Journal of Clinical Oncology, 2007 ASCO Annual Meeting 25(18S), 2007. e-Pub 2007.
32. Hassan M, Dagohoy C, Leary C, Li D, Yao JC. Risk factors for low-grade neuroendocrine carcinoma (LGNET): Hospital-based case-control study in US. Journal of Clinical Oncology, 2007 ASCO Annual Meeting 25(18S), 2007. e-Pub 2007.
33. Mares J, Eisner MP, Dagohoy C, Phan A, Rashid A, Evans D, Yao J. Population based study of islet cell carcinoma. Journal of Clinical Oncology, 2007 ASCO Annual Meeting 25(18S), 2007. e-Pub 2007.
34. Yao JC, Phan A, Chang D, Wolff R, Jacobs C, Mares J, Gupta S, Meric-Bernstam F, Rashid A. Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in advanced low grade neuroendocrine carcinoma (LGNET). Journal of Clinical Oncology, 2007 ASCO Annual Meeting 25(18S), 2007. e-Pub 2007.
35. Lenz H, Lee FC, Haller DG, Singh D, Benson AB, Strumberg D, Yanagihara RH, Yao JC. Extended safety and efficacy data on S-1 plus cisplatin in patients with advanced gastric carcinoma in a multi-center phase II study. J Clin Oncol 4083, 2006. e-Pub 2006.
36. Yao JC, Phan AT, Jacobs C, Mares, JE, Meric-Bernstam. Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in patient with advanced low grade neuroendocrine carcinoma (LGNET). J Clin Oncol 10688, 2006. e-Pub 2006.
37. Al-Feaie WB, Tseng JF, Gay G, Patel-Parekh L, Mansfield PF, Pisters PW, Yao JC, Feig BW. The influence of ethnicity on the outcome in patients with gastric adenocarcinoma: Results from the National Cancer Database, 2006. e-Pub 2006.
38. Perez RP, Lewis LD, Cohen GI, Hwang J, Malik S, Marshall JL, Baker J, Phan AT, Yao JC. First-in-human phase I pharmacokinetic trial of NS-9, a lipsomal poly(I): poly(C), in patients with liver metastases from various primary cancers. J Clin Oncol 13016, 2006. e-Pub 2006.
39. Phan AT, Wang L, Xie K, Zhang J, Rashid A, Evans D, Vauthey J, Abdalla E, Abbruzzese JL, Yao JC. Association of VEGF expression with poor prognosis among patients with low-grade neuroendocrine carcinoma. J Clin Oncol 4091, 2006. e-Pub 2006.
40. Mares J, Worah S, Mathew S, Charnsangavej C, Chen H, Ajani J, Hoff P, Phan A, Yao JC. Increased rates hypertension (HTN) among patients with advanced carcinoid treated with bevacizumab. ASCO 41st Annual Meeting, 2005. e-Pub 2005.
41. Yao JC, Ng C, Hoff PM, Phan A, Hess K, Chen H, et al. Improved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab. J Clin Oncol 23(16S):309s, 2005. e-Pub 2005.
42. Ajani J, Phan A, Yao JC, Lee F, Singh D, Haller D, Benson A, Lenz J, Yanagihara R, Strumberg D. Multi-center phase II study of S-1 plus cisplatin in patients with advanced gastric carcinoma (AGC), . ASCO 41st Annual Meeting, 2005. e-Pub 2005.
43. Mares J, Worah S, Mathew S, Charnsangavej C, Chen H, Ajani J, Hoff P, Phan A, Yao JC. Increased rates hypertension (HTN) among patients with advanced carcinoid treated with bevacizumab. J Clin Oncol 4087, 2005. e-Pub 2005.
44. Scott L, Evans T, Yao JC, Benson A, Mulcahy M, Thomas A, Decatris M, Falk S, Rudoltz M, Ajani J. Pegamotecan (EZ-246), a novel PEGylated camptothecin conjugate, for treatment of adenocarcinomas of the stomach and gastroesophageal (GE) junction: Preliminary results of a single-agent phase 2 study. ASCO 40th Annual Meeting, 2004. e-Pub 2004.
45. Yao JC, Charnsangavej S, Faria C, Szklaruk J, Chen H, Hoff P, Phan A, Yeung J, Abbruzzese J, Ajani J. Rapid decrease in blood flow (BF), blood volume (BV), and vascular permeability (PS) in carcinoid patients treated with bevacizumab. ASCO 40th Annual Meeting, 2004. e-Pub 2004.
46. Tseng T, Mansfield P, Feig B, Pisters P, Ajani J, Yao JC. The effect of ethnicity on presentation, pattern of metastasis and survival in gastric adenocarcinoma at a single center. ASCO 40th Annual Meeting, 2004. e-Pub 2004.
47. Ajani JA, Yao JC, Faust J, Carr K, Houghton A, Urrea P. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma (AGC). ASCO 40th Annual Meeting, 2004. e-Pub 2004.
48. Carr K, Yao JC, Rashid A, Yeung S, Szklaruk J, Baker J, Vauthey JN, Curley S, Ellis L, Ajani J. A Phase II trial of imatinib in patients with advanced carcinoid tumor. ASCO 40th Annual Meeting, 2004. e-Pub 2004.
49. Mares J, Yao JC, Wang L, Wei D, Gong W, Hassan M, Wu T, Mansfield P, Ajani J, Xie K. Sp1 expression is associated with increased VEGF, advanced stage, and poor survival in patients with resected gastric cancer (GC). ASCO 40th Annual Meeting, 2004. e-Pub 2004.
50. Swisher S, Ajani JA, Komaki R, Putnam J, Walsh G, Liao Z, Yao JC, Faust J, Wu TT, Roth J. CPT-11-Taxotere-5-FU Regimen for Induction and Concurrent Chemoradiotherapy Prior to Surgery in Patients with Resectable Esophageal or GEJ Carcinoma. Proc Am Soc Clin Oncol 22:272, 2003. e-Pub 2003.
51. Hou A, Elasmar SA, Lozano R, Hoff P, Wolff RA, Abbruzzese JL, Ajani JA, Carr K, Rashid A, Yao JC. A Pilot Study of Irinotecan plus Cisplatin in Patients with Metastatic High-Grade Neuroendocrine Carcinoma. Proc Am Soc Clin Oncol 22:375, 2003. e-Pub 2003.
52. Yao JC, Yeung SJ, Rashid A, Szklaruk J, Baker J, Carr K, Vauthey N, Ellis L, Curley S, Ajani JA. Early Results of a Phase II Trial of Imatinib in Patients with Advanced Carcinoid Tumor. Proc Am Soc Clin Oncol 22:371, 2003. e-Pub 2003.
53. Chang BB, Bleyer W, Faust J, Yao JC, Craig C, JAjani JA. Phase II Study of Bryostatin-1 (NSC 339555) Plus Paclitaxel in Patients with Metastatic or Unresectable Locally Advanced Adenocarcinoma of Stomach or Gastroesophageal Junction. Proc Am Soc Clin Oncol 22:264, 2003. e-Pub 2003.
54. Hassan MM, Yao JC. Increased Incidence of Carcinoid (C) Tumors and Improved Survival of Patients with Metastases From 1973-1987 as Compared To 1988-1999. Proc Am Soc Clin Oncol 22:373, 2003. e-Pub 2003.
55. Baker J, Schnirer II, Yao JC, et al. Phase II trial of irinotecan in patients with advanced carcinoid tumor. Proc Am Soc Clin Oncol 20:166a, 2002. e-Pub 2002.
56. Zheng L, Le X, Wei D, Wang L, Peng Z, Wu TT, Yao JC, Ajani JA, Xie K. Expression and Regulation of Interleukin-8 in Human Gastric Adenocarcinoma. Gastrointestinal Cancer Research Conference, 2002. e-Pub 2002.
57. Agarwal, B, Yao JC, Roth JA. Role of EUS performed after pre-operative chemoXRT in esophageal cancer. Am Assoc of Thor Surg, 2002. e-Pub 2002.
58. Gupta S, Yao JC, Wallace S, Ajani JA, Hicks ME. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Gastrointestinal Cancer Research Conference, 2002. e-Pub 2002.
59. Yao JC, Najam AA, Rashid A, et al. Clinical and pathologic features of patients with carcinoma associated with Barrett’s metaplasia: An analysis of 1,162 patients with esophageal or esophagogastric junction cancer. Proc Am Soc Clin Oncol 21:135a, 2002. e-Pub 2002.
60. Yao JC, Hassan M. Increasing Incidence of Carcinoid in the United States. SEER 1992-1999. Gastrointestinal Cancer Research Conference, 2002. e-Pub 2002.
61. Yang Q, Cleary KR, Yao JC, Swisher SG, Ajani JA, Rashid A, Hamilton SR, Wu TT. Significance of post-chemoradiation biopsy in predicting residual tumor status in resection specimens of esophageal carcinoma. USCAP, 2002. e-Pub 2002.
62. Phan A, Hasham N, Yao JC, Schnirer I, Najam A, Reddy S, Chang S, Wu T, Ajani J. Survival of Patients with Advanced Gastric Cancer in Stie and Histology-Grade Specific. Gastrointestinal Cancer Research Conference, 2002. e-Pub 2002.
63. Ebrahimi E, Phan A, Yao JC, Mansfield PF, Pisters PW, Feig BW, Ajani JA. Phase II clinical trial of Rubitecan against advanced gastric adenocarcinoma. Proc Am Soc Clin Oncol 21:150a, 2002. e-Pub 2002.
64. Agarwal, B, Yao JC, Roth JA. Determinants of response to chemoradiation in patients with esophageal cancer. Am Assoc of Thor Surg, 2002. e-Pub 2002.
65. Swisher SG, Yao JC, Roth JA. Computed tomography (CT), endoscopy, barium swallow and positron emission tomography (PET) are not predictive of a complete pathologic response following preoperative chemoradiation in esophageal cancer patients. Am Assoc of Thor Surg, 2002. e-Pub 2002.
66. Lazo G, Yao JC, Najam AA, et al. Clinical risk factors for peritoneal metastases in esophagastric junction carcinoma (GEJC). Proc Am Soc Clin Oncol 21:141a, 2002. e-Pub 2002.
67. Wang L, Zheng L, Wei D, Le X, Peng Z, Wu TT, Yao JC, Ajani JA, Xie K. Unique Expression Patterns of Transcription Factor Sp1 in Normal and Malignant Gastric Tissues. Gastrointestinal Cancer Research Conference, 2002. e-Pub 2002.
68. Phan A, Najam A, Yao JC, Mansfield P, Pisters PW, Feig BW, Ajani JA. Differences in location, histology, and pattern of metastasis in gastric cancer among Caucasians, Hispanics, and African Americans. Proc Am Soc Clin Oncol 21:136a, 2002. e-Pub 2002.
69. Najam AA, Yao JC, Lenzi R, et al. Linitis plastica is common in women and in poorly differentiated and signet ring cell histologies: An analysis of 217 patients. Proc Am Soc Clin Oncol 21:166a, 2002. e-Pub 2002.
70. Yao JC, Chiang S, Yu C, et al. The effects of gender and ethnicity on gastric cancers localization. Proc Am Soc Clin Oncol 20:165a, 2001. e-Pub 2001.
71. Xiong Q, Yao JC, Phan A, et al. Frequency of esophagogastric junction involvement among upper gastrointestinal cancers. Proc Am Soc Clin Oncol 20:430a, 2001. e-Pub 2001.
72. Najam AA, Yao JC, Giacco G, et al. The effects of gender, race, histology, and tumor location on patterns of metastases in gastric cancer. Proc Am Soc Clin Oncol 20:166a, 2001. e-Pub 2001.
73. Yao JC, Schnirer II, Chiang S, et al. Different patterns of gastric cancer localization in men and women. Proc Am Soc Clin Oncol 19:652a, 2000. e-Pub 2000.
74. Schnirer II, Komaki R, Yao JC, et al. A study of concurrent 5FU/paclitaxel and radiotherapy in patients with carcinoma of the upper gastrointestinal tract. Proc Am Soc Clin Oncol 19:472a, 2000. e-Pub 2000.

Book Chapters

1. Yao JC, Clarke CN, Evans DB. Pancreatic Neuroendocrine Tumors. In: CANCER Principles & Practice of Oncology. 11th Edition. Wolters Kluwer, 1352-1367, 2019.
2. Schmidt C, Blum Murphy M, Yao JC, Crane CH. Carcinoma of the stomach. In: Cancer Medicine. 9th Edition. WILEY Blackwell, 1091-1101, 2017.
3. Balachandran A, Fleming J, Callender G, Krishnan S, Yao J. Pancreatic Neuroendocrine Tumors. In: Oncologic Imaging: A Multidisciplinary Approach. Elsevier, 193-210, 2012.
4. Yao JC, Rindi G, Evans DB. Pancreatic Neuroendocrine Tumors. In: CANCER Principles & Practice of Oncology. 9th Edition. Wolters Kluwer, 1489-1502, 2011.
5. Yao JC, Rindi G, Evans DB. Pancreatic Endocrine Tumors. In: CANCER Principles & Practice of Oncology. 8th Edition. DeVita, 2008.
6. Yao JC, Xie K. Development of Novel Therapeutic Agents for Neuroendocrine Tumors. In: A Century of Advances in Neuroendocrine Tumor Biology and Treatment. Felsenstein CCCP, 370-377, 2008.
7. Yao JC, Gupta S, Vauthey JN, Evans DB. Management of Nonfunctional Islet Cell - Carcinomas of the Pancreas. In: Advanced Therapy in Surgical Oncology. BC Decker Inc, 443-448, 2008.
8. Phan AT, Yao JC, Allam SR, Ajani JA. Carcinoma of the Esophagus and Gastric Carcinoma. In: The M D Anderson Manual of Medical Oncology. McGraw-Hill, 2006.
9. Chang BB, Phan AT, Yao JC. Neuroendocrine Carcinoma. In: The M D Anderson Manual of Medical Oncology. McGraw-Hill, 2006.
10. Phan A, Yao JC. Esophageal Cancer and Gastric Cancer. In: Cancer Matrix. 4th. Advanced Medical Publishing, 2006.
11. Yao JC. Carcinoma of the Stomach. In: Holland-Frei: Cancer Medicine 7. 7, 1268-91, 2006.
12. Phan A, Yao JC. Esophageal Cancer and Gastric Cancer. In: Cancer Matrix Manual. 4th Edition. Advanced Medical Publishing, 2006.
13. Yao JC, Crane C, Mansfield PF. Gastric cancer. In: Cancer Medicine. 7th Edition. BC Decker, 2005.
14. Talamonti MS, Stuart KE, Yao JC. Neuroendocrine Tumors of the Gastrotintesinal Tract: How Aggressive Should We Be? . In: American Society of Clinical Oncology 2004 Educational Book, 2004.
15. Mansfield PF, Yao JC, Crane C. Gastric cancer. In: Cancer Medicine. 6th Edition. BC Decker, 2003.
16. Yao JC, Ajani JA. Therapy of Localized Gastric Cancer: Preoperative and Postoperative Approaches. In: ESMO 2002 Educational Book, 2002.
17. Yao JC, Ajani JA. Management of neuroendocrine cancers of the gastrointestinal tract:Carcinoid tumors. In: The Principles and Practice of Gastrointestinal Oncology. Oxford University Press, 2001.
18. Yao JC, Kouvaraki M, Gupta S. Management of Metastatic Islet Cell Carcinoma. In: Pancreatic Cancer, 2000.

Books (edited and written)

1. Caplin M, Yao JC. Handbook of Gastroenteropancreatic and Thoracic NeuroendocrineTumours. Bio Scientifica, 2011.
2. Yao JC, Hoff PM, Hoff AO, et al. Neuroendocrine Tumors. Humana Press, 2011.
3. Yao JC, Hoff PM. Hematology Oncology Clinics of North America, 2007.

Letters to the Editor

1. de Sousa LG, Liu S, Bhosale P, Altan M, Darbonne W, Schulze K, Dervin S, Yun C, Mahvash A, Verma A, Futreal A, Gite S, Cuentas EP, Cho WC, Wistuba I, Yao JC, Woodman SE, Halperin DM, Ferrarotto R. Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study. Oral Oncol 151: 106747, 2024.
2. Kulke MH, Bergsland EK, Yao JC. Glycemic Control in Patients with Insulinoma Treated with Everolimus. N Engl J Med 360: 195-197, 2009.
3. Yao JC, Kvols LK. Octreotide LAR in Carcinoid: How to Dose?. Pancreas 37: 337-338, 2008.